Scorpion, Eli Lilly

Eli Lilly to buy Scorpion Therapeutics' cancer therapy for up to $2.5 billion
Eli Lilly said on Monday it plans to buy Scorpion Therapeutics' experimental cancer therapy for up to $2.5 billion in cash to expand its pipeline of cancer treatments. The company will acquire Scorpion's experimental oral therapy,
Eli Lilly scientific chief Skovronsky says Scorpion deal ‘checked all the boxes’
Eli Lilly’s chief scientific officer said the company purchased a cancer drug from the startup Scorpion Therapeutics because it "checked all the boxes."
Lilly pads cancer drug pipeline with Scorpion deal
The pharma will spend up to $2.5 billion to acquire an experimental PI3K inhibitor from Scorpion, which will spin out a new company holding its employees and other assets.
Eli Lilly targets Scorpion Therapeutics to expand reach in oncology
After selling its PI3Kα program to Eli Lilly, Scorpion will spinout out a different entity, which will be owned by the biotech’s current shareholders.
Eli Lilly to acquire Scorpion Therapeutics’ STX-478 program for up to $2.5B
Eli Lilly (LLY) and Scorpion Therapeutics announced a definitive agreement for Lilly to acquire Scorpion’s PI3Kalpha
Lilly acquires Scorpion Therapeutics in deal worth up to $2.5B
Eli Lilly and Co. announced Monday that it is buying Boston-based Scorpion Therapeutics and its targeted breast cancer treatment program in a deal worth up to $2.5 billion.
Eli Lilly to buy cancer drug developer Scorpion Therapeutics for up to $2.5 billion
Eli Lilly said on Monday it would buy cancer therapy developer Scorpion Therapeutics for up to $2.5 billion in cash. Lilly will acquire Scorpion's experimental oral therapy, STX-478, which is currently being tested in early-stage trials for breast cancer and other advanced solid tumors.
Eli Lilly To Buy Scorpion Therapeutics' Experimental Cancer Therapy For Up To $2.5 Bln In Cash
Eli Lilly and Company (LLY) on Monday said it has agreed to buy Scorpion Therapeutics' experimental cancer therapy PI3Ka inhibitor
Eli Lilly to Buy Scorpion Therapeutics Drug Program in $2.5 Billion Deal
Eli Lilly agreed to acquire Scorpion Therapeutics’ breast cancer treatment program for up to $2.5 billion in cash.
Eli Lilly to Acquire Scorpion Therapeutics' Breast Cancer Candidate For up to $2.5 Billion
Eli Lilly (LLY) agreed to acquire an experimental treatment for breast cancer and other advanced solid tumors from Scorpion Therapeutics for up to $2.5 billion. The purchase price includes an upfront payment and subsequent amounts that Scorpion's shareholders would receive as certain regulatory and sales milestones are achieved.
Eli Lilly to acquire Scorpion for up to $2.5B
Eli Lilly (NYSE:LLY) has agreed to buy Scorpion Therapeutics' lead drug program for up to $2.5B in cash and spin out the remaining company as a new entity focused on precision medicine. Scorpion's lead drug asset,
How the scorpion lollipop became an Arizona icon — even though it's not made here
Ever wondered how gem-like lollipops with a scorpion inside are made? Here's how and why they've become so popular in Arizona ...
FierceBiotech2d
JPM25: Eli Lilly strikes $2.5B Scorpion buyout in twist to breast cancer tale
Eli Lilly is reenergizing its attempt to challenge Novartis and Roche for a breast cancer market, kicking off the J.P. Morgan ...
TransMedics says claims made by Scorpion Capital ‘have no merit’
Group addressed what we believe are inaccurate and misleading claims made in a short-seller report issued by Scorpion ...
Mortal Kombat 1 Trailer Shows Off Conan the Barbarian and T-1000 Terminator
In his Brutality, Conan can be seen grabbing Scorpion by the shoulder, while tossing his sword straight up into the air. Conan then stabs his enemy under the chin with a smaller blade, using a volley ...
Lilly to pay $2.5B for Boston biotech's lead cancer drug
Scorpion Therapeutics Inc. is selling its lead drug in testing for breast cancer and other advanced solid tumors, to Eli ...